Is it really impossible to stop taking ixazomib?

Ixazomib is an oral proteasome inhibitor mainly used to treat multiple myeloma. As an effective anti-tumor drug, ixazomib interferes with the growth and survival of tumor cells by inhibiting intracellular proteasome activity, thereby promoting their death. For patients with multiple myeloma, ixazomib is often used as part of combination therapy, often with other drugs (such as lenalidomide, dexamethasone, etc.). However, the question of whether "the drug cannot be discontinued" depends on many factors, including the patient's condition, treatment response, and whether drug resistance has developed.

From a clinical perspective, ixazomib does not require long-term, uninterrupted administration from the outset. Generally, after a patient has been treated for a period of time, the doctor will decide whether to continue using ixazomib based on the patient's treatment response, tumor control, and side effects. Ixazomib is usually administered as part of maintenance therapy for most patients, especially if the patient is in remission. Doctors may adjust the treatment plan based on the patient's clinical condition, including extending or shortening the treatment cycle, adjusting the dose, or even suspending treatment.

During the treatment of some patients, if drug resistance or tumor recurrence occurs, the treatment strategy may need to be adjusted or even switched to other drugs. But for some patients who achieve a good response and have no significant side effects, ixazomib may continue as part of long-term maintenance therapy. After stopping the medication, the doctor will carefully monitor the patient's condition changes, conduct follow-up visits and adjust the treatment plan as necessary.

Generally speaking, long-term use of ixazomib is not an absolute requirement, and whether to discontinue the drug needs to be comprehensively decided based on the patient's specific condition, treatment response, and side effects. During the treatment process, patients should maintain close communication with their doctors, conduct regular examinations, and make treatment adjustments according to the doctor's recommendations. For patients with multiple myeloma, timely adjustment and scientific management of early treatment are of great significance to improving survival rate and quality of life.

Reference materials:https://www.ninlaro.com/